- Imatinib, sold
under the
brand names Gleevec and
Glivec (both
marketed worldwide by Novartis)
among others, is an oral
targeted therapy medication used...
-
carbamazepine (Tegretol),
valsartan (Diovan),
imatinib mesylate (Gleevec/
Glivec),
cyclosporine (Neoral/Sandimmune),
letrozole (Femara), methylphenidate...
-
develop this disease. It is
treated with
imatinib (Gleevec in
United States,
Glivec in Europe) or
other drugs. The five-year
survival rate is 90%. One subtype...
-
Glivec in Europe).
Other pharmacological inhibitors are
being developed,
which are more
potent and/or are
active against the
emerging Gleevec/
Glivec resistant...
- India—roughly 16,000 people—receive
Glivec free of charge... and it has
provided more than $1.7
billion worth of
Glivec to
Indian patients in its support...
-
formulation that can
substitute Glivec, were
distributed in the
local market since 1993.
Novartis had
filed a
patent for
Glivec in 1997. An
exclusive marketing...
-
fight against drug
maker Novartis on the
issue of
patent of
cancer drug
Glivec. On the
night before Yakub Memon was
scheduled to be executed,
Anand Grover...
- imatinib, sunitinib, regorafenib,
ripretinib and avapritinib.
Imatinib (
Glivec/Gleevec), an
orally administered drug
initially marketed for
chronic myelogenous...
- of this new
class of
drugs was
imatinib mesylate (marketed as
Gleevec or
Glivec),
approved by the US Food and Drug
Administration (FDA) in 2001. Imatinib...
- Novo
Nordisk Diabetes mellitus type 1 and 2 Dec-1990 Mon-20XX 26 Gleevec,
Glivec Imatinib 498,149 7.22%
Novartis Leukemia May-2001 Jan-2015 27 Herceptin...
